Skip to content
Clinical Trials – home
LuxembourgBack to Luxembourg

Clinical trials in Libramont-Chevigny

46 clinical trials in Libramont-Chevigny, Luxembourg. Every trial is listed in the EU Clinical Trials Register and updated daily.

Libramont-Chevigny at a glance
46
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

46 trials in Libramont-Chevigny

Open in trial search

Graves' disease

Recruiting

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ZL-1310
  • Sponsor:Zai Lab (US) LLC

Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

Registered drugNo placebo
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AstraZeneca AB

A Phase III Randomized Trial of Trilaciclib Dihydrochloride versus Placebo in Adults with Limited‑Stage Small Cell Lung Cancer

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Trilaciclib dihydrochloride
  • Sponsor:Pharmacosmos A/S

Study of Rinatabart Sesutecan with glatiramer acetate in patients with advanced gastrointestinal cancers

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Comparing AZD5335 with mirvetuximab soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:AZD5335
  • Sponsor:AstraZeneca AB

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:Relay Therapeutics Inc.

Prostate cancer

Recruiting

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Study on Apixaban and Edoxaban for Preventing Stroke in Patients with Recent Perioperative Atrial Fibrillation After Noncardiac Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Hamilton Health Sciences Corporation

Study on the Effectiveness of 2LEBV and 2LXFS for Reducing Fatigue in Patients with Epstein-Barr Virus Infection

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Interferon Alfa
  • Sponsor:Labo'Life Belgium

Other cities in Luxembourg

The busiest research cities in the country

All 2 cities in Luxembourg

Clinical research in Libramont-Chevigny

What the registry says about research in the country

01 Breast Cancer Research

Multiple clinical trials focusing on advanced breast cancer treatments, particularly for patients with different receptor statuses including HER2-negative and hormone receptor-positive cases. Studies evaluate novel therapeutic combinations and treatment approaches.

  • Hormone receptor-positive treatments
  • Triple-negative breast cancer therapies
  • Combination therapy approaches
02 Lung Cancer Studies

Innovative research exploring non-small cell lung cancer treatments and new therapeutic options for extensive-stage small cell lung cancer. Trials evaluate various treatment combinations and compare effectiveness with standard therapies.

  • Advanced NSCLC treatments
  • Immunotherapy combinations
  • Novel therapeutic approaches
03 Gynecological Oncology

Comprehensive studies investigating treatments for various gynecological cancers, including endometrial, ovarian, and fallopian tube cancers. Research focuses on combining immunotherapy with standard treatments.

  • Endometrial cancer therapies
  • Ovarian cancer treatments
  • Advanced peritoneal cancer approaches
04 Urological Cancer Research

Clinical trials examining new treatments for bladder cancer and prostate cancer, including studies of innovative therapeutic combinations and maintenance therapies.

  • Non-muscle invasive bladder cancer
  • Metastatic prostate cancer
  • Novel combination approaches
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.